Search Results

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

Oramed Pharmaceuticals Inc. announced that on September 21, 2023, Oramed and Scilex Holding Company entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note to Oramed.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Oramed Pharmaceuticals Inc. announced that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. to establish a joint venture based on Oramed’s oral drug delivery technology.

Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.

Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.

Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.

Oramed Pharmaceuticals Inc. announced the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023.